Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation

Oncogene

Volumn 34, Issue 4, 2015, Pages 445-454

  Sahasrabuddhe, A A ^a   Chen, X ^a   Chung, F ^a   Velusamy, T ^a   Lim, M S ^a   Elenitoba Johnson, K S J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

EZH2; lymphoma; protein degradation; SCFb TrCP ubiquitin ligase

Indexed keywords

BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; EZH2 PROTEIN, HUMAN; HISTONE; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; POLYCOMB REPRESSIVE COMPLEX 2; PROTEASOME;

GENETICS; HEK293 CELL LINE; HUMAN; LYMPHOMA; METABOLISM; METHYLATION; MUTATION; PHOSPHORYLATION; PHYSIOLOGY;

BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; HEK293 CELLS; HISTONES; HUMANS; JANUS KINASE 2; LYMPHOMA; METHYLATION; MUTATION; PHOSPHORYLATION; POLYCOMB REPRESSIVE COMPLEX 2; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 85028198623     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.571     Document Type: Article

References (39)

1. Piunti A, Pasini D. Epigenetic factors in cancer development: polycomb group proteins. Fut Oncol 2011; 7: 57-75.
2. Mills AA. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer 2010; 10: 669-682.
3. Erhardt S, Su IH, Schneider R, Barton S, Bannister AJ, Perez-Burgos L et al. Consequences of the depletion of zygotic and embryonic enhancer of zeste 2 during preimplantation mouse development. Development 2003; 130: 4235-4248.
4. Martin-Perez D, Piris MA, Sanchez-Beato M. Polycomb proteins in hematologic malignancies. Blood 2010; 116: 5465-5475.
5. Richly H, Aloia L, Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis 2011; 2: e204.
6. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010; 7: 299-313.
7. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J 2004; 23: 4061-4071.
8. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-349.
9. Simon JA, Kingston RE. Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Mol Cell 2013; 49: 808-824.
10. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009; 10: 697-708.
11. Surface LE, Thornton SR, Boyer LA. Polycomb group proteins set the stage for early lineage commitment. Cell Stem Cell 2010; 7: 288-298.
12. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
13. Bodor C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013; 122: 3165-3168.
14. Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23: 677-692.
15. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-112.
16. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA 2013; 110: 7922-7927.
17. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8: 890-896.
18. Popovic R, Shah MY, Licht JD. Epigenetic therapy of hematological malignancies: where are we now? Ther Adv Hematol 2013; 4: 81-91.
19. Sahasrabuddhe AA, Dimri M, Bommi PV, Dimri GP. betaTrCP regulates BMI1 protein turnover via ubiquitination and degradation. Cell Cycle 2011; 10: 1322-1330.
20. Zoabi M, Sadeh R, de Bie P, Marquez VE, Ciechanover A. PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins. Biochem Biophys Res Commun 2011; 408: 393-398.
21. Yu YL, Chou RH, Shyu WC, Hsieh SC, Wu CS, Chiang SY et al. Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. EMBO Mol Med 2013; 5: 531-547.
22. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005; 6: 9-20.
23. Chen H, Ma H, Inuzuka H, Diao J, Lan F, Shi YG et al. DNA damage regulates UHRF1 stability via the SCF(beta-TrCP) E3 ligase. Mol Cell Biol 2013; 33: 1139-1148.
24. Tan MK, Lim HJ, Harper JW. SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitinmediated proteasomal degradation. Mol Cell Biol 2011; 31: 3687-3699.
25. Liu H, Cheng EH, Hsieh JJ. Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev 2007; 21: 2385-2398.
26. Dimri M, Bommi PV, Sahasrabuddhe AA, Khandekar JD, Dimri GP. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Carcinogenesis 2010; 31: 489-495.
27. Emanuele MJ, Elia AE, Xu Q, Thoma CR, Izhar L, Leng Y et al. Global identification of modular cullin-RING ligase substrates. Cell 2011; 147: 459-474.
28. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-736.
29. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-449.
30. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369-381.
31. Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell 2003; 11: 1445-1456.
32. Kaneko S, Li G, Son J, Xu CF, Margueron R, Neubert TA et al. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev 2010; 24: 2615-2620.
33. Argetsinger LS, Kouadio JL, Steen H, Stensballe A, Jensen ON, Carter-Su C. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol 2004; 24: 4955-4967.
34. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 2007; 21: 49-54.
35. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010; 116: 5247-5255.
36. Morey L, Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 2010; 35: 323-332.
37. Ciferri C, Lander GC, Maiolica A, Herzog F, Aebersold R, Nogales E. Molecular architecture of human polycomb repressive complex 2. Elife 2012; 1: e00005.
38. Yadav AK, Sahasrabuddhe AA, Dimri M, Bommi PV, Sainger R, Dimri GP. Deletion analysis of BMI1 oncoprotein identifies its negative regulatory domain. Mol Cancer 2010; 9: 158.
39. Velusamy T, Palanisamy N, Kalyana-Sundaram S, Sahasrabuddhe AA, Maher CA, Robinson DR et al. Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2013; 110: 3035-3040.